Omnicell, Inc.

NASDAQ:OMCL

Medical - Healthcare Information Services

Healthcare
$34.66 -1.49%

-$0.58 today

Market cap
$1.59B
Beta
0.96
P/E (TTM)
84.1
EPS (TTM)
$0.45
52W Low $26.85High $55.00

Volume 0.34M

Average 0.57M

OMCL Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Omnicell, Inc.NASDAQ: OMCL

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 45.3%

Gross margin was 45.3% in Q1 FY2026, up 4.2 pp from a year earlier. On a trailing-twelve-month basis it was 43.5%, up 0.3 pp year over year. Over 3 fiscal years it narrowed by 2.6 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
45.3%+3.8 pp QoQ
Last fiscal yearDec 2025
42.9%+0.5 pp YoY
LTMMar 2026
43.5%+0.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+4.2 pp——
1 year+0.5 pp——
3 years-2.6 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
42.9%
Year-over-year change
+0.5pp

Gross Margin vs competitors

How OMCL compares with its peers on the latest reported figures

  • OMCL's LTM Mar 2026 gross margin of 43.5% is the 8th highest of the 11 companies compared; the peer median is 62.1%.
  • Its year-over-year change of +0.3 pp is the 6th highest of 11, against a peer median of +0.0 pp.
  • Over three fiscal years its change of -2.6 pp compares with a peer median of +1.8 pp.
OMCL Competitors Peer median
Gross Margin for OMCL and competitors
Company Period LTM level YoY 3-year change
GDRXGoodRx Holdings, Inc.LTM Mar 202686.6% -7.3 pp+1.3 pp
TXG10x Genomics, Inc.LTM Sep 202671.9% +3.0 pp-7.6 pp
OMDAOmada HealthLTM Mar 202666.2% +4.6 pp+17.7 pp
PHRPhreesia, Inc.LTM Apr 202665.8% -2.2 pp+6.8 pp
TDOCTeladoc Health, Inc.LTM Mar 202665.6% -4.9 pp+0.4 pp
SDGRSchrödinger, Inc.LTM Sep 202658.5% +0.4 pp-0.1 pp
SSIISS Innovations International, Inc.LTM Mar 202648.4% +11.6 pp+12.4 pp
OMCLOmnicell, Inc.LTM Mar 202643.5% +0.3 pp-2.6 pp
UFPTUFP Technologies, Inc.LTM Jun 202628.5% -0.3 pp+2.8 pp
PGNYProgyny, Inc.LTM Jun 202624.6% +2.2 pp+2.4 pp
ASTHAstrana Health, Inc.LTM Mar 20269.3% -2.9 pp-8.1 pp
Peer median (excluding OMCL) 62.1%+0.0 pp+1.8 pp

Competitors are the stored peer set for OMCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.13B1.3B1.15B1.11B1.18B
Cost of Revenue577.37M706.96M647.18M641.24M676.8M
Gross Profit554.65M588.99M499.93M471M508.04M
Gross Margin49.0%45.4%43.6%42.3%42.9%
Research & Development75.72M104.97M93.29M90.41M87.74M
Selling, General & Admin389.43M486.34M425.97M380.25M408.64M
Operating Expenses465.15M591.31M519.26M470.67M496.38M
Depreciation & Amortization84.93M99.17M95.56M89.76M86.63M
EBITDA173.33M96.85M79.98M119.87M101.87M
EBITDA Margin15.3%7.5%7.0%10.8%8.6%
Operating Income89.51M(2.32M)(19.33M)337K11.67M
Operating Margin7.9%-0.2%-1.7%0.0%1.0%
Interest Income0014.76M24.9M11.9M
Interest Expense22.39M130K04.53M3.91M
Other Income / Expenses(23.5M)(130K)(779K)25.26M(340K)
Income Before Tax66.01M(2.45M)(20.11M)25.59M11.33M
Pre-Tax Margin5.8%-0.2%-1.8%2.3%1.0%
Income Tax Expense(11.84M)(8.1M)263K13.06M9.27M
Net Income77.85M5.65M(20.37M)12.53M2.05M
Net Margin6.9%0.4%-1.8%1.1%0.2%
EPS (Basic)1.790.13(0.45)0.270.04
EPS (Diluted)1.620.12(0.45)0.270.04
Weighted Avg Shares43.48M44.4M45.21M46.05M45.97M
Weighted Avg Shares (Diluted)47.94M45.89M45.21M46.26M46.36M

Omnicell, Inc.

NASDAQ:OMCL

Intrinsic Alpha fair value

Locked

Current Price

$34.66

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.